ELEV 0.78 (-63.38%)
US28623U1016BiotechnologyBiotechnology

Elevation Oncology (ELEV) Stock Highlights

0.78 | -63.38%
2024-08-07 05:16:25
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Statistics

Range Today
0.75 1.03
Volume Today 19.25M
Range 1 Year
0.36 5.83
Volume 1 Year 285.81M
Range 3 Year
0.36 13.39
Volume 3 Year 504.61M
Range 10 Year
0.36 16.22
Volume 10 Year 509.52M

Highlights

Market Capitalization 129.49M (small)
Floating Shares 28.61M
Current Price 0.78
Price To Earnings -2.91
Price To Book 1.62
Earnings Per Share -0.85
Payout Ratio 0%

Performance

Latest -63.38%
1 Month -72.92%
3 Months -79.26%
6 Months -73.91%
1 Year -22%
3 Years -90.83%
5 Years -94.43%
10 Years -94.43%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.